预期应用
ELISA法定量测定人血浆或其它相关液体中TAT含量。
实验原理
本试剂盒应用双抗体夹心酶标免疫分析法测定标本中TAT水平。用纯化的抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入TAT抗原、生物素化的抗人TAT抗体、HRP标记的亲和素，经过彻底洗涤后用底物TMB显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的TAT呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），计算样品浓度。
Intended use
This immunoassay kit allows for the specific measurement of human TAT concentrations in plasma.
Introduction
Thrombin-antithrombin (TAT) complexes formed following the neutralization of thrombin by antithrombin III (AT) have been used as a surrogate marker for thrombin generation. High plasma level of TAT complexes has been suggested to alter hemostatic activation in argentine hemorrhagic fever, chronic dialysis patients, and toxemia of pregnancy. Whereas low plasma level of TAT complexes is found in type 1 (insulin-dependent) diabetes, neonatal respiratory distress syndrome, and primary untreated cancer. TAT complexes are a useful marker to predict morphological changes in chronic aortic dissection.
Test principle
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for TAT has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any TAT present is bound by the immobilized antibody. An enzyme-linked monoclonal antibody specific for TAT is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of TAT bound in the initial step. The color development is stopped and the intensity of the color is measured.
| 
